Key Details
Price
$3.40Annual ROE
57.54%Beta
1.05Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Feb 29, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Puma Biotechnology beats third-quarter 2024 estimates for both the top and the bottom lines. The company updates its 2024 financial guidance.
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - CEO, President and Chairman Maximo Nougues - CFO Jeff Ludwig - Chief Commercial Officer Conference Call Participants Ed White - H.C. Wainwright Divya Rao - TD Cowen Operator Good afternoon.
Puma Biotech (PBYI) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.17 per share a year ago.
Puma Biotechnology (PBYI) beats second-quarter estimates for both the top and the bottom line.
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q2 2024 Earnings Call August 1, 2024 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, Investor Relations Alan Auerbach - Chief Executive Officer, President and Chairman Maximo Nougues - Chief Financial Officer Jeff Ludwig - Chief Commercial Officer Conference Call Participants Marc Frahm - TD Cowen Ed White - H.C. Wainwright Operator Good afternoon.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Sales of Puma Biotechnology's (PBYI) sole marketed drug, Nerlynx, have been declining in recent quarters. Stiff competition in the target market is also a woe.
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that two abstracts for its drug Alisertib to be presented at the 2024 ASCO Annual Meeting are now posted on ASCO.org.
Puma Biotechnology (PBYI) announces a smaller-than-anticipated loss in the first quarter of 2024. The company is sticking to its revenue forecast for the year.
Puma Biotechnology, Inc. (NASDAQ:PBYI) will be hosting its Q1 2024 Earnings Conference Call on May 2, 2024 at 4:30 PM ET. Present at the call will be Mariann Ohanesian, Alan Auerbach, Jeff Ludwig, and Maximo Nougues. Participants include Ed White from H.C. Wainwright and Divya Rao from TD Cowen. The operator greets everyone with a good afternoon.
FAQ
- What is the primary business of Puma Biotechnology?
- What is the ticker symbol for Puma Biotechnology?
- Does Puma Biotechnology pay dividends?
- What sector is Puma Biotechnology in?
- What industry is Puma Biotechnology in?
- What country is Puma Biotechnology based in?
- When did Puma Biotechnology go public?
- Is Puma Biotechnology in the S&P 500?
- Is Puma Biotechnology in the NASDAQ 100?
- Is Puma Biotechnology in the Dow Jones?
- When was Puma Biotechnology's last earnings report?
- When does Puma Biotechnology report earnings?
- Should I buy Puma Biotechnology stock now?